The high-risk model associated with SYTL4 predicts poor prognosis and correlates with immune infiltration in AML
{{output}}
Acute myeloid leukemia (AML) currently lacks a definitive cure. Studies have highlighted the involvement of SYTL4 expression levels in neoplasms, yet its specific roles in AML remain unexplored in the literature. Utilizing the TCGA and XENA databases, this stu... ...
